These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 15944334)
1. Rapamycin: a new string to the antiproteinuric bow? Brunskill NJ J Am Soc Nephrol; 2005 Jul; 16(7):1878-9. PubMed ID: 15944334 [No Abstract] [Full Text] [Related]
2. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease. Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016 [TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. Diekmann F; Rovira J; Carreras J; Arellano EM; Bañón-Maneus E; Ramírez-Bajo MJ; Gutiérrez-Dalmau A; Brunet M; Campistol JM J Am Soc Nephrol; 2007 Oct; 18(10):2653-60. PubMed ID: 17804674 [TBL] [Abstract][Full Text] [Related]
4. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Diekmann F; Campistol JM Nephrol Dial Transplant; 2006 Mar; 21(3):562-8. PubMed ID: 16361278 [No Abstract] [Full Text] [Related]
5. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Saurina A; Campistol JM; Piera C; Diekmann F; Campos B; Campos N; de las Cuevas X; Oppenheimer F Nephrol Dial Transplant; 2006 Feb; 21(2):488-93. PubMed ID: 16280369 [TBL] [Abstract][Full Text] [Related]
6. Considerations in sirolimus use in the early and late post-transplant periods. Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662 [TBL] [Abstract][Full Text] [Related]
7. Rapamycin and chronic kidney disease: beyond the inhibition of inflammation. Liu Y Kidney Int; 2006 Jun; 69(11):1925-7. PubMed ID: 16724087 [TBL] [Abstract][Full Text] [Related]
8. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992 [TBL] [Abstract][Full Text] [Related]
9. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606 [TBL] [Abstract][Full Text] [Related]
10. Sirolimus--challenging current perspectives. Buhaescu I; Izzedine H; Covic A Ther Drug Monit; 2006 Oct; 28(5):577-84. PubMed ID: 17038868 [TBL] [Abstract][Full Text] [Related]
11. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Ramos-Barrón A; Piñera-Haces C; Gómez-Alamillo C; Santiuste-Torcida I; Ruiz JC; Buelta-Carrillo L; Merino R; de Francisco AL; Arias M Lupus; 2007; 16(10):775-81. PubMed ID: 17895299 [TBL] [Abstract][Full Text] [Related]
12. Sirolimus in de novo heart transplant recipients with severe renal impairment. Vazquez de Prada JA; Vilchez FG; Cobo M; Ruisanchez C; Valls MF; Ruano J; Piñera C; Duran RM Transpl Int; 2006 Mar; 19(3):245-8. PubMed ID: 16441775 [TBL] [Abstract][Full Text] [Related]